Compare · BDX vs PDEX
BDX vs PDEX
Side-by-side comparison of Becton Dickinson and Company (BDX) and Pro-Dex Inc. (PDEX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and PDEX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $42.39B, about 237.0x PDEX ($178.8M).
- Over the past year, BDX is down 15.6% and PDEX is up 13.4% - PDEX leads by 28.9 points.
- BDX has been more active in the news (6 items in the past 4 weeks vs 4 for PDEX).
- BDX has more recent analyst coverage (25 ratings vs 0 for PDEX).
- Company
- Becton Dickinson and Company
- Pro-Dex Inc.
- Price
- $153.13-0.47%
- $53.55-4.13%
- Market cap
- $42.39B
- $178.8M
- 1M return
- +8.85%
- -17.30%
- 1Y return
- -15.56%
- +13.36%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 6
- 4
- Recent ratings
- 25
- 0
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Pro-Dex Inc.
Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and maxocranial facial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.
Latest BDX
- Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Mike Garrison to Retire from BD
- BD to Announce Financial Results for its Third Quarter of Fiscal 2026
- EVP & President Connected Care Muhsin Bilal was granted 14,342 shares and covered exercise/tax liability with 1,935 shares, increasing direct ownership by 43% to 41,359 units (SEC Form 4) (for withholding tax)
- SEC Form 11-K filed by Becton Dickinson and Company
- SEC Form 11-K filed by Becton Dickinson and Company
- EVP, Chief Revenue Officer Feld Michael sold $11,460 worth of shares (75 units at $152.80) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 21,009 units (SEC Form 4)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $160,226 worth of shares (1,100 units at $145.66) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 13,172 units (SEC Form 4)
- BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System
- New insider Sinha Manish claimed ownership of 8,806 shares (SEC Form 3)
Latest PDEX
- Director Domingo Angelita Rebamontan sold $47,146 worth of shares (998 units at $47.24), decreasing direct ownership by 5% to 18,779 units (SEC Form 4)
- Chief Financial Officer Charlton Alisha was granted 10,800 shares and covered exercise/tax liability with 3,897 shares, increasing direct ownership by 40% to 24,170 units (SEC Form 4) (tax liability)
- Chief Executive Officer Van Kirk Richard Lee Jr was granted 14,800 shares and covered exercise/tax liability with 5,279 shares, increasing direct ownership by 11% to 99,228 units (SEC Form 4) to cover withholding tax
- Director Domingo Angelita Rebamontan was granted 6,800 shares and covered exercise/tax liability with 2,488 shares, increasing direct ownership by 28% to 19,777 units (SEC Form 4) (for withholding tax)
- Pro-Dex Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Chief Executive Officer Van Kirk Richard Lee Jr sold $626,248 worth of shares (10,000 units at $62.62) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 89,707 units (SEC Form 4)
- Pro-Dex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Pro-Dex Inc.
- Pro-Dex, Inc. Announces Fiscal 2026 Third Quarter and Nine Month Results
- Pro-Dex Inc. filed SEC Form 8-K: Leadership Update